Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer.
DOI:
https://doi.org/10.26641/2307-0404.2014.3.30341Keywords:
breast cancer, immunohistochemical status, diagnostics, clinical progression, overall survivalAbstract
Modern global guidelines in oncology consider treatment of various forms of breast cancer according to molecular tumor subtype. Steroid receptors, epidermal growth factor receptors, p53, Ki67 proliferative activity index and others are the key indicators of aggressiveness of malignant breast tumors. The material for this study was the retrospective study of the standard set of breast cancer immunohistochemical markers (estrogen receptors, progesterone, epidermal growth factor type 2) in 8171 patients. 4 groups of patients - luminal A, luminal B, triple negative and HER2-neu positive subtypes of tumors were identified according to immunohistochemical status. We analyzed overall survival without relapse in 491 patients with breast cancer, clinical data and data of immunohistochemical studies were matched. Based on the investigation it was determined that in the early stages of the disease (1-2) luminal A subtype of cancer is often diagnosed. In the late stages the most common subtype is HER2-neu positive breast cancer. Herewith, patients with luminal A subtype of cancer have the best performance of the overall survival (OS ) (32,91±2,33 months), and the worst results were found in patients with HER2 - neu positive breast cancer (22,58±1,28 months). The data obtained determine HER2 - neu positive subtype as the most aggressive type of breast cancer, and the luminal A subtype – as the least aggressive one.References
Добренький М.Н. Молекулярно-биологи¬чес¬кие и биохимические факторы прогноза при раке мо¬лочной железы (обзор литературы) [Електронний ресурс] / М.Н. Добренький, А.М. Добренький // Вест¬ник РНЦРР Минздрава России. – 2005.-№5.- Режим доступу до журналу: http://vestnik.rncrr.ru/vestnik/ v5/papers/litdobr_v5.htm
Минимальные клинические рекомендации Ев¬ро¬пейского Общества Медицинской Онкологии (ЕSМО) [Редакторы русского перевода: проф. С.А. Тюляндин, к.м.н. Д.А. Носов; проф. Н.И. Пере¬вод¬чикова]. — М.: Издат. группа РОНЦ им. Н. Н. Бло¬хина РАМН, 2010.— 436 с.
Молекулярные типы рака грудной железы, опре¬деленные на основе иммуногистохимических маркеров: клинико-биологические особенности и прогноз течения / И.Б. Щепотин, А.С. Зотов, Р.В. Лю¬бота, Н.Ф. Аникусько [и др.] // Клинич. онкология. – 2012. - № 8 (4). - С. 1-4.
Неоадъювантная системная терапия рака мо¬лочной железы. Руководство для врачей / В.Ф. Се¬ми¬глазов, А.Г. Манихас, Т.Ю. Семиглазова, Бессонов [и др.]. – СПб.: Аграф+, 2012. – 112 с.
О лечении местных рецидивов рака молочной железы / Ю.В. Думанский, И.Е. Седаков С.О. Алиева, М.Н. Ше¬п¬ляков // Злоякісні новоутворення. - 2002. - Вип.2. - С.56-57.
Переводчикова Н.П. Лекарственная терапия ра¬ка молочной железы / Н.П. Переводчикова; под ред. Пе¬реводчиковой Н.И., Стениной М.Б. – М.: Практика, 2014. – 204 с.
Пожарисский К.М. Прогностическое и пред¬ска¬зательное значение иммуногистохимических мар¬ке¬ров: руководство по иммуногистохимической ди¬агнос¬тике опухолей человека / К.М. Пожарисский, Е.Е. Лееман; под ред. Петрова С.В. – Казань, 2012. - С. 402-404.
Харченко В.П. Маммология: национальное ру¬ководство / В.П. Харченко; под ред. В.П. Харченко, Н.И. Рожковой. – М.: ГЭОТАР-Медиа, 2009. – 328 с.
ASCO–CAP HER2 Test Guideline Recom¬men¬dations [Summary of Guideline 2007 and 2013 Recom¬mendations]. – USA:College of American Pathologist. – 2013. - 5 p.
Cordera F. Steroid receptors and their role in the biology and control of breast cancer growth / F. Cordera, V.C. Jordan // Semin. Oncol. – 2006. – Vol. 33, N 6. – P. 631-641.
Handbook of cancer diagnosis and treatment eva¬luation/ H.-J. Schmol, L.V. Veer, J. Vermorken, D. Schrij¬vers. – New York, London: Informa healthcare, 2009. – 156 p.
Molecular subtypes in breast cancer evaluation and management: divide and conquer / J. Peppercorn, C.M. Perou, L.A. Carey [et. al.] // Cancer Invest. - 2008. – Vol.26. – P. 1-10.
Update of Recommendations for the Use of Tu¬mor Markers in Breast Cancer / J. Clinical Oncology. – 2007. – Vol. 25, N 33. – P. 5287-5312.
Dobrenky MN, Dobrenky AM. [Molecular. biolo¬gical and biochemical prognostic factors in breast cancer]. Vestnik PNCPP Minzdrava Rossii; 2005. Russian. Avai¬lable from: http://vestnik.rncrr.ru/vestnik/v5/papers/ litdobr_v5.htm 5.
Tulandin SA, Nosov DA, Perevodchikova NI. [Mi¬nimal Clinical Recommendations of Europe Society of Medical Oncology (ESMO) (Translation into Rus¬sian)]. Russian Academy of Medical Sciences. 2010;436. Russian.
Shepotin IB, Zotov AS, Lyubota RV, Anikusko NF. Molecular types of breast cancer, defined on the basis of immunohistochemical markers: clinical and biological features and prognosis. Klinichna Oncologia. 2012;8(4):1-4. Russian.
Semiglazov VF, Manikhas AG, Semiglazova TU. [Neoadjuvant system therapy for breast cancer]. Guide for phisicians. 2012;112. Russian.
Dumansky UV, Sedakov IE Alieva SO, Shep¬lyakov MN. [On the treatment of local recurrence of breast cancer]. Zloyakisni novoutvorennya. 2002;2:56-57. Russian.
Perevodchikova NP, Stenina MB. [Drug therapy for breast cancer]. Moscow. 2014;204. Russian.
Pozarissky KM, Leeman EE, Petrov SV. [Prog¬nostic and predictive value of immunohistochemical mar¬kers]. 2012;402-4. Russian.
Kharchenko VP, Rozkova NI. [Mammology: na¬tional guideline]. 2009;328. Russian.
College of American Pathologist ASCO–CAP HER2 Test Guideline Recommendations. Summary of Guideline 2007 and 2013 Recommendations. 2013;5.
Cordera F, Jordan VC. Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol. 2006;33(6):631-41.
Schmol H-J, Veer LV, Vermorken J, Schrijvers D. Handbook of cancer diagnosis and treatment eva¬lua¬tion. New York / London Informa healthcare. 2009;156.
Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1-10.
Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology. N 33 (November 20), 2007;25:5287-312.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
